TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03324581
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPC-64005-matching placebo film coated tablets and atomoxetine-matching placebo gelatin capsules
Study: NCT04543305
Drug: PRT1419
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRT1419 will be administered orally
Study: NCT00796289
Drug: placebo GnRH patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo transdermal patch with a high target delivery of placebo(every 90 minutes). New patch to be applied every 12 hours.
Study: NCT06521034
Drug: FHND-9041
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Phase I, using a 3+3 design, dose escalation and expansion studies were conducted at doses of 40, 80, 120 and 180 mg/day. At least 3 patients were enrolled in each dose arm, and no dose-limiting toxicities were observed. With a plateau observed at 120 mg/day, the 80 mg/d and 120mg/d groups were selected for dose expansion. The 80mg/d queue has expanded by 36 patients, and the 120mg/d queue has expanded by 39 patients. In Phase Ⅱ, after comprehensive analysis and consultation, at least 30 patients were enrolled according to the inclusion and exclusion criteria. 37 patients with locally advanced or metastatic EGFR-mutated NSCLC receiving first-line treatment were enrolled.
Study: NCT04316598
Drug: Cannabis Sativa
Normalized name: CANNABIS SATIVA SEED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive a total of 4 inhaled doses of 20 mg of tetrahydrocannabinol (THC) in 3 days.~Cannabis is provided as a medical grade cannabis flos (Cannabis sativa dried female flower) containing THC 22% and cannabidiol \<1%, supplied by Bedrocan®.~To avoid the respiratory disadvantages of smoking, a vaporization device (Mighty® Medic) will be used to inhale the drug. The prepared capsules will contain 90 mg of Cannabis flos, equivalent to 20 mg of THC.
Study: NCT03134196
Drug: Masked Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Placebo
Study: NCT03696784
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 500 mg/m2/day administered by IV over 3 consecutive days
Study: NCT01030328
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 sugar pills by mouth once a day.
Study: NCT02355977
Drug: minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Periocline dental ointment
Study: NCT01483833
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ointment applied intra-anally twice daily for 14 days
Study: NCT04126070
Drug: Androgen Deprivation Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given per standard care for duration of study. Regimens include Leuprolide (Lupron Depot) intramuscularly every 3 months, Goserelin acetate (Zoladex) subcutaneously every 4 weeks, or degarelix (Firmagon) subcutaneously every month per standard of care.
Study: NCT00548587
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01954082
Drug: myo-Inositol 5% Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abbott Nutrition Division, Abbott Laboratories is supplying myo-Inositol 5% Injection to the clinical centers for the duration of the trial.~Inositol: myo-Inositol 5% Injection is an isotonic, preservative-free, sterile 5% solution of myo-inositol in water containing 0.5 gm sodium chloride per liter (8.55mM), pH 6.5-7.5. It is administered via IV infusion using syringe pump over 15-30 minutes twice per day at 12-hour intervals at a dose of 80 mg inositol/kg/day (40 mg inositol/kg/dose), which is equivalent to 1.6 mL/kg/day (0.80 mL/kg/dose).
Study: NCT01954082
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: % glucose(dextrose)
Study: NCT02405104
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04529772
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator
Study: NCT04529772
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Investigational Product
Study: NCT04529772
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Investigational Product
Study: NCT02811354
Drug: AZD9291
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration as a single daily dose of 80 mg
Study: NCT00538525
Drug: Doxorubicin, Docetaxel, Cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin, Docetaxel, Cisplatin
Study: NCT00285207
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 days of 28 day cycle for 2 cycles
Study: NCT01334242
Drug: Schedule A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosing 1 hour before breakfast
Study: NCT01334242
Drug: Schedule B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosing 0.5 hour before breakfast
Study: NCT01334242
Drug: Schedule C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosing immediately before breakfast
Study: NCT01334242
Drug: Schedule D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosing immediately before lunch
Study: NCT01097876
Drug: Placebo PF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo BID for 7 days (period 1) 7 day washout (no drug) 7 days of 5 mg donepezil QD; 14 days 10 mg QD (Period 2) 7 days of 10 mg donepezil QD and Placebo BID (Period 3)
Study: NCT02749123
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: patch with no active manufactured to have the same look and feel as Lidoderm 10cmx 14 cm transdermal patch sealed in its own pouch
Study: NCT02059031
Drug: GSK1265744 Reference formulation
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1265744 (micronized) reference formulation is available as 30 mg tablet to be orally administered with 240 mL of water
Study: NCT02059031
Drug: GSK1265744 New formulation 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1265744 (micronized) New formulation 1 is available as 30 mg tablet to be orally administered with 240 mL of water
Study: NCT02059031
Drug: GSK1265744 New formulation 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1265744 (un-micronized) New formulation 2 is available as 30 mg tablet to be orally administered with 240 mL of water
Study: NCT02935374
Drug: Macrolide
Normalized name: Macrolide
Approvals — FDA: no, EMA: no, PMDA: no
Description: The children with acute otitis media with a know allergy to amoxicillin or amoxicillin-clavulanate will be treated with macrolide and monitored separately
Study: NCT01541202
Drug: rhNRG-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 hours per day i.v drip for the first 10 days (0.6ug/kg/day), followed by weekly 10 minutes i.v bolus (0.8ug/kg/day), from the 3rd week for 23 weeks
Study: NCT01541202
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 hours per day i.v drip for the first 10 days (0ug/kg/day), followed by weekly 10 minutes i.v bolus (0ug/kg/day), from the 3rd week for 23 weeks
Study: NCT04263051
Drug: standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second line chemotherapy at the choice of the investigator
Study: NCT03179501
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline
Study: NCT01206387
Drug: placebo comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered to affected area twice a day for 28 days
Study: NCT00706849
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mL matching placebo
Study: NCT01032759
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: BID
Study: NCT02294552
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01896700
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalating matched dose of placebo
Study: NCT03613532
Drug: Decitabine/cedazuridine
Normalized name: decitabine/cedazuridine 35 mg-100 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 3: 3 doses for 8 cycles
Study: NCT00531986
Drug: HAART
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will continued their current HAART
Study: NCT01475071
Drug: Metvix and natural daylight PDT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methyl aminolevulinate, cream 160mg/g.One session at baseline and a second session administration at week 12 for lesions showing non-complete response and new lesions on target area.
Study: NCT03254368
Drug: ZGN-1061
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZGN-1061 is a methionine aminopeptidase 2 inhibitor
Study: NCT03254368
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo has the same excipients and appearance as ZGN-1061
Study: NCT02206243
Drug: Embozene Microspheres
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraarterial application
Study: NCT02809261
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline is safe for perineural injection.
Study: NCT01555957
Drug: intravenous lipid
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous given daily for 6 weeks
Study: NCT00753545
Drug: matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo bid
Study: NCT00201435
Drug: Paclitaxel weekly in combination with capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00201435
Drug: Docetaxel every 3 week in combination with capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00409929
Drug: AEB071
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03676985
Drug: ZKAB001 5mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5mg/kg/times bi-week IV administration of ZKAB001
Study: NCT03676985
Drug: ZKAB001 10mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg/kg/times bi-week IV administration of ZKAB001
Study: NCT03676985
Drug: ZKAB001 15mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15mg/kg/times bi-week IV administration of ZKAB001
Study: NCT01602198
Drug: Placebo transdermal patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo transdermal patch 1/day for 6 months
Study: NCT01077531
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo for intravenous infusion
Study: NCT00369785
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weeks 1-6: One tablet per day Weeks 7-24: Two tablets per day
Study: NCT02946632
Drug: triple combination therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xigduo (metformin 1000mg + dapagliflozin 10mg) saxagliptin 5mg
Study: NCT02946632
Drug: Stepwise add-on therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: metformin -\> glimepirde -\> sitagliptin
Study: NCT00048620
Drug: N-acetylgalactosamine 4-sulfatase
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00755508
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramelteon placebo-matching tablets, orally, once daily and gabapentin placebo-matching capsules, orally, once daily for up to one week.
Study: NCT00244842
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01203254
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet: 3 times daily 2 tablets
Study: NCT03849027
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The sham inhaler will have one droplet of methoxyflurane applied to the outer surface, but no drug in the vaporization chamber to give off the prominent odour with no analgesic effect, partially blinding the participants to the test.
Study: NCT01178255
Drug: homeopathic q-potencies
Normalized name: Chew Q
Approvals — FDA: no, EMA: no, PMDA: no
Description: individualised homeopathic medicines
Study: NCT01178255
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT01948310
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of placebo twice per day vs. Ranolazine 1000mg twice per day
Study: NCT01483586
Drug: kanglaite gelcap
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 KLTc gelcap capsules four times a day throughout the study (12 months). Each gelcap contains .45g KLT per capsule
Study: NCT01483586
Drug: Kanglaite gelcap
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 KLTc gelcaps taken four times a day throughout the study (12 months). Each gelcap contains .45g KLT
Study: NCT03607643
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard of care chemotherapy for Stage IV colon or rectal cancer, will include leucovorin 350 mg/m2 IV over 2 hours Day 1, 5-FU 400 mg/m2 IV bolus followed 2400 mg/m2 IV over 46 hours, oxaliplatin 100 mg/m2 IV Day 1, bevacizumab 5 mg/kg IV day1. Irinotecan can be substituted for oxaliplatin.
Study: NCT04199741
Drug: SC16.56, Phase I, Cohort 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5mg
Study: NCT03875560
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive
Study: NCT03788395
Drug: Symbicort Turbohaler without Turbo+
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symbicort Turbohaler (Budesonide and Formoterol Fumarate Dihydrate) without Turbo+ for three months.
Study: NCT01910116
Drug: Shinbaro
Approvals — FDA: no, EMA: no, PMDA: no
Description: GCSB-5 (Shinbaro) is a mixture of six purified oriental herb extracts in a fixed ratio, namely, Saposhnikovia divaricata Schischk, Glycine max Merrill, Cibotium barometz J. Smith, Eucommia ulmoides Oliver, Achyranthes japonica Nakai, and Acanthopanax sessiliflorus Seem
Study: NCT01910116
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study medication and placebo were identical in appearance.
Study: NCT02528422
Drug: Acyl-Ghrelin
Normalized name: gellan gum (low acyl)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03194217
Drug: BEN-2001
Normalized name: Pen-Ben
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bavisant dihydrochloride monohydrate for oral use
Study: NCT03194217
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01237340
Drug: Saizen®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of Saizen® (recombinant human growth hormone, r-hGH) solution for injection will be administered subcutaneously for 26 weeks. Dosage regimen will be in accordance with marketed formulation of Saizen® (freeze-dried formulation), based on locally approved product labeling.
Study: NCT01507454
Drug: estradiol, 25 mcg
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal tablets for 6-12 weeks according to product labelling
Study: NCT02375646
Drug: LMW Heparin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01856374
Drug: Pravastatin 20mg
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2x2 randomization by the treatment of dyslipidemia (In patients of dyslipidemia: pravastatin 20mg/day vs. atorvastatin 40mg and the types of the implanted cypher vs xience.
Study: NCT01236118
Drug: LY2439821
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously
Study: NCT03712228
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buffer without active ingredient
Study: NCT01652261
Drug: BEACOPPesc
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02038829
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02038829
Drug: SUN101 3 mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: SUN-101 3 mcg bid
Study: NCT00913588
Drug: Fluoxetine HCl 20 mg Capsules Under Fasting Conditions (Geneva Pharmaceutical, Inc.)
Normalized name: fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00913588
Drug: Fluoxetine HCl 20 mg Capsules Under Fed Conditions (Geneva Pharmaceutical, Inc.)
Normalized name: fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00913588
Drug: Prozac Fluoxetine HCl 20 mg Capsules Under Fed Conditions (Dista)
Normalized name: fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04001205
Drug: Anticoagulation Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long term oral anticoagulation with VKA (vitamin K antagonist) or NOAC (non-vitamin K oral anticoagulant)
Study: NCT03476746
Drug: LEO 90100 foam
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A foam formulation of the active comparator Dovobet® ointment
Study: NCT03476746
Drug: Dovobet® ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ointment formulation containing same active ingredients as LEO 90100 foam
Study: NCT02077751
Drug: biotin labelled RBCs
Normalized name: Biotin
DrugBank: Biotin (DB00121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Autologous red blood cells are biotin labelled and transfused to the subject. Survival of these red blood cells is tracked through examination of blood samples until no biotin labelled red blood cells remain.
Study: NCT02266966
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02742467
Drug: Perindopril plus Hydrochlorothiazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2
Study: NCT02079922
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.
Study: NCT02079922
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06678552 or placebo will be administered as an extemporaneously prepared solution either once daily (QD), every 12 hours (Q12H), or every 8 hours (Q8H) for 14 days.
Study: NCT04509674
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04636229
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo is 0.9% normal saline: 4 mL to be injected IA.
Study: NCT02742467
Drug: Amlodipine plus Hydrochlorothiazide
Normalized name: amlodipine / hydrochlorothiazide / valsartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 3
Study: NCT00331123
Drug: Testosterone Transdermal System
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: testosterone patch, 300mcg/day, changed every 3-4 days for up to 52 weeks
Study: NCT00331123
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo patch,changed every 3-4 days for 24 weeks during double blind phase
Study: NCT00268307
Drug: Autologous, Unfractionated Bone Marrow Mononuclear Cells
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary infusion of Autologous, Unfractionated Bone Marrow Mononuclear Cells. Dose is 100,000,000 cells. One time infusion over 20 minutes.
Study: NCT00732771
Drug: LCI699
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04150588
Drug: Efrin drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: The amount that the eyelid rise after Erin drops before surgery
Study: NCT00821990
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: The administration of chemotherapy regimen (docetaxel or irinotecan) will be determined at the discretion of investigator, and depends on the patient's previous chemotherapy.
Study: NCT03570749
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT04336228
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20mg placebo tablet daily for 3-4 weeks.
Study: NCT03845322
Drug: Placebo pills
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo pill is a vegetarian cellulose capsule, with cellulose powder inside. The composition is cellulose and magnesium stearate.
Study: NCT00335270
Drug: fos-amprenavir calcium, ritonavir
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00955383
Drug: GSK2190915
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2190915 is a high affinity 5-lipoxygenase-activating protein (FLAP) inhibitor.
Study: NCT00955383
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT00240474
Drug: Telmisartan 80 mg + hydrochlorothiazide 12.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00240474
Drug: Amlodipine 10 mg + hydrochlorothiazide 12.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02497976
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline
Study: NCT01389206
Drug: observational study with patients treated with Tracleer, Ventavis, Veletri, Opsumit and/or Uptravi
Approvals — FDA: no, EMA: no, PMDA: no
Description: observational study with patients treated with Tracleer, Ventavis, Veletri, Opsumit and/or Uptravi
Study: NCT02561585
Drug: LEO 124249
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00847119
Drug: capecitabine (Xeloda)
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 900 mg/m2 two times a day concomitant during radiotherapy period
Study: NCT01903525
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects presenting with a new concussion within 4 days of their initial injury will be identified and screened for eligibility from the investigators' regularly scheduled clinic patients. Subjects who enroll will complete 5 scheduled visits, although additional visits may be clinically indicated for symptom evaluation and treatment. All assessments done for this study are routinely done as part of the standard clinic visits for concussion at the Sports Medicine Center. Subjects will be randomized to either DHA or placebo in a 1:1 ratio, and receive enough DHA or placebo capsules to reach the target dose of 2 g of DHA per day (or placebo) until the day of their next appointment. Subjects will be instructed to take 4 capsules (2 at breakfast and 2 at dinner) for 12 weeks.
Study: NCT00107926
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00875277
Drug: LEO 29102 cream
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00875277
Drug: LEO 29102 Cream Vehicle
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00875277
Drug: Daivobet® Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00930982
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of matching placebo twice a day
Study: NCT02276911
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes